PDAC is a highly aggressive malignant cancer and the 3rd leading cause of cancer related deaths in the US. Currently, treatment options for patients are limited due to late detection of the tumors and lack of effective therapies. The aggressive nature of PDAC is in part due to the desmoplastic tumor microenvironment. MiR-200c regulates epithelial-to-mesenchymal transition and extracellular remodeling for effective treatment of aggressive tumors. In this study, we investigate the effectiveness of MR molecular imaging of extradomain-B fibronectin, an extracellular matrix oncoprotein associated with EMT, for non-invasive monitoring of PDAC tumor response to miR-200c therapy in a mouse model.